State ID: Date	of Incident Specimen Collec	tion ( <i>mm-dd-yyyy</i> ):	Surveillance	Officer Initials
Form Approved OMB No. 0920-0978	CANDIDEMIA	2025 CASE REPORT FO	DRM	
Patient name:(Last, First		Medical Record I	No.:	
	t, MI)			
Address:(Number, Street, Apt. No.)		•		
		•	t isolate):	
(City, State)	(Zip Code)	Acc No. (subseq	isolate):	
Address type:  1 Residential 2 Post office 3	☐Long-term care facility 4 ☐	Corrections 5 Military 6	☐Homeless 7 ☐Other 8	☐Insufficient 9 ☐Missing
Phone no.: ( )				
Check if not a case:				
Reason not a case: Out of catch	· · · · · ·	□Not candidemia □Unable	to verify address Other (	specify):
SURVEILLANCE OFFICER INFO				
1. Date reported to EIP site:	3. Was case first identified through audit? 1 Yes 0 No	i. Previous candidemia epi □Yes 0 □No 9 □Unknow	<b>sode?</b> n	6. CRF status: 7. SO's initials:
		a. If yes, enter state		2 □Pending
2. Date review completed:	4. Isolate available?  1 □Yes 0 □No	Ds:		3 Chart unavailable
DEMOCRAPHIES.				
DEMOGRAPHICS				
8. State ID:	10. State:	11. C	ounty:	
9. Patient ID:				
12. Lab ID where positive culture	e was identified:			
13. Date of birth (mm-dd-yyyy):	14. Age:		15. Sex:	
	1	]days 2 □mos 3 □yrs	☐Male ☐Female	
16. Weight:	17. Height:		40 PMT (	***************************************
Ibs oz. Of	R ft		18. BMI: (record only	<u></u>
kg	cm	Unknown	available)	Unknown
19. Race and/or Ethnicity (select	all that apply):			
☐American Indian orAlaska Native	☐Middle Eastern o	or North African		
□Asian	☐Native Hawaiian	orPacific Islander		
☐Black orAfrican American	□White			
☐Hispanic or Latino	□Unknown			
LABORATORY DATA				
20. Date of Incident Specimen Co	ollection (DISC) (mm-dd-yyy,	y):		
21. Location of Specimen Collect	ion:			
☐Hospital Inpatient	☐ Outpatient		LTCF	
Facility ID:	Facility ID:	·	Facility ID:	
☐ ICU	☐ Emergency Room	_	LTACH	
☐ Burn unit	Clinic/Doctor's office		Facility ID:	
☐ Surgery/OR	☐ Dialysis center		Autopsy	
☐ Radiology ☐ Other inpatient	☐ Surgery ☐ Observational/clinica		Other Unknown	
☐ Other Impatient	Other outpatient	ar decision drift	Olkilowii	
22. Candida species from initial p	positive blood culture (check	all that apply):		
☐ Candida albicans (CA)	☐ Candida dub	bliniensis (CD)	☐ Candida, other (CO) spec	ifv:
Candida auris (CAU)	☐ Candida lusi		☐ Candida, germ tube nega	
1				

Public reporting burden of this collection of information is estimated to average 40 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

State ID: Date of Incide		_ Date of Incider	nt Specimen Collection ( <i>mm-dd-yyyy</i> ):			Surveillance Officer Initials				
☐ Candida glabrata (CG) ☐ Candida parapsilosis (CP) ☐ Candida tropicalis (CT)		)	☐ Candida krusei (CK) ☐ Candida guilliermond	dii (CGM)		☐ Candida species (CS) ☐ Pending				
		lity testing (chec	k here $\square$ if no testing don	ne/no test repo	rts availab	le):				
	Date of culture	Species	Drug MIC			Interpretation				]
			Amphotericin B		□s	□SDD □	]I 🗆 R	□NI	□ND	
		1 □CA	Anidulafungin (Eraxis)		□s	□SDD □	]I 🔲R	□NI	□ND	
		13 □CAU 2 □CG	Caspofungin (Cancidas)		□s	□SDD □	]I 🔲R	□NI	□ND	
		3 □CP 4 □CT	Fluconazole (Diflucan)		□s	□SDD □	]I 🗆 R	□NI	□ND	
		5 □CD 6 □CL	Flucytosine (5FC)		□s	□SDD □	]I 🗆 R	□NI	□ND	
		7 □CK	Itraconazole (Sporanox)		□s	□SDD □	]I 🗆R	□NI	□ND	
		8 □CGM 9 □CO	Micafungin (Mycamine)		□s	□SDD □	]I 🗆 R	□NI	□ND	
		10 □CGN 11 □CS	Posaconazole (Noxafil)		□s	□SDD □	]I 🗆 R	□NI	□ND	
		12 ☐Pending	Rezafungin (Rezzayo)		□s	□SDD □	]I 🗆R	□NI	□ND	
			Voriconazole (Vfend)		□s	□SDD □	]I 🗆 R	□NI	□ND	
			Amphotericin B		□s	□SDD □	]I 🗆 R	□NI	□ND	
		1 □CA	Anidulafungin (Eraxis)		□s	□SDD □	]I 🔲R	□NI	□ND	
		13 □CAU 2 □CG	Caspofungin (Cancidas)		□s	□SDD □	]I 🗆R	□NI	□ND	
		3 □CP 4 □CT	Fluconazole (Diflucan)		□s	□SDD □	]I 🗆R	□NI	□ND	
		5	Flucytosine (5FC)		□s	□SDD □	]I 🗆R	□NI	□ND	
		6 □CL 7 □CK	Itraconazole (Sporanox)		□s	□SDD □	]I 🗆 R	□NI	□ND	
		8	Micafungin (Mycamine)		□s	□SDD □	]I 🗆 R	□NI	□ND	
		10 □CGN 11 □CS	Posaconazole (Noxafil)		□s	□SDD □	]I 🗆 R	□NI	□ND	
		12 Pending	Rezafungin (Rezzayo)		□s	□SDD □	]I 🗆 R	□NI	□ND	
			Voriconazole (Vfend)		□s	□SDD □	]I 🗆 R	□NI	□ND	
24. Did	the patient have	a PCR molecular	test for <i>Candida</i> (e.g., T2)	, in the 6 days	before or t	wo days af	ter the D	ISC?		
1 ∐Yes	0 □No 9 □Unk	nown								
25a. If y	es, test type:		_							
25b. Res	sult:		_							

Version: Short Form 2024 Last Updated: 07/29/2023 Page **2** of **10** 

State ID:	Date of Incident Specimen Collection (mm-dd-yyyy): Surveillance Officer Initials
25. Any subsequent positiv	e Candida blood cultures in the 29 days after, not including the DISC? 1 Yes 0 No 9 Unknown
25a. If yes, provide dates of al	subsequent positive Candida blood cultures and select the species:
Date Drawn (mm-dd-yyyy)	Species identified*
	CA CAU CG CP CT CD CL CK CGM CO: CGN CS Pend
	CA CAU CG CP CT CD CL CK CGM CO: CGN CS Pend
	if additional <i>Candida</i> species (different from original), if another <i>C. glabrata</i> (even if original was <i>C. glabrata</i> ), or if AFST results available for original)
	Candida blood culture on the day of or in the 29 days after the DISC (in which no blood cultures after this ive in the 29 days after the DISC)? $1 \square Yes 0 \square No 9 \square Unknown$
26a. If yes, date of negative bl	ood culture:
colonized with a multi-drug 1 □Yes 0 □No 9 □Ur	days before the DISC, was the patient known to be colonized with or being managed as if they were resistant organism (MDRO) (e.g., on contact precautions)? MDROs include CRE, CRPA, CRAB, MRSA, and VI known  (Enter up to 3 pathogens):
	organisms isolated from blood cultures on the day of or in the 6 days before the DISC:
1	
28a. If yes, additional organism	ns ( <i>Enter up to 3 pathogens</i> ):,,
29. Did the patient have an apply):  None Unknown	y of the following types of suspected or confirmed infection related to their Candida infection? (check all that
☐Abdominal infection	☐Urinary tract infection ☐Pulmonary infection ☐Endocarditis
Hepatobiliary or pancreati	
Abscess (specify):	
Peritonitis/peritoneal fluid	☐ Osteomyelitis ☐ Eyes ☐ Skin /wound infection ☐ Endophthalmitis
☐ Splenic	☐ Chorioretinitis
30. Was the patient known	to be colonized with <i>Candida auris</i> before their candidemia diagnosis?
1 □Yes 0 □No 9 □Ur	
MEDICAL ENCOUNTERS	
31. Was the patient hospita	lized on the day of or in the 6 days after the DISC? 1 Yes 0 No 9 Unknown
31a. If yes, Date of first admission:	
Hospital ID:	Unknown
31b. Was the patient transferr 1 □Yes 0 □No 9 □	
If yes, enter up to two transfe	rs:
Date of transfer:	
Hospital ID:	——————————————————————————————————————
L	

Version: Short Form 2024 Last Updated: 07/29/2023 Page **3** of **10** 

State ID:	_ Date of Incident Specimen Collection (mm-dd-yyyy):	Surveillance Officer Initials
31c. Where was the patient the DISC? ( <i>Check one</i> )	located prior to admission or, if not currently hospitalized, wl	here was the patient located on the 3rd calendar day before
1 □Private residence	4 □LTACH	6 □Correctional or detention facility
2 Hospital inpatient	Facility ID:	8 Drug/alcohol rehabilitation
Facility ID:	,	
3 □LTCF	5 ☐Homeless	7  □ Other
Facility ID:		
		9  □Unknown
_	ICU in the 14 days before, not including the DISC?	
1 □Yes 0 □No 9	□Unknown	
33. Was the patient in an	ICU on the day of incident specimen collection or in the	13 days after the DISC?
1 □Yes 0 □No 9	□Unknown	
34. Did the patient receiv	ve dialysis or renal replacement therapy (RRT) in the 30 d	lays before the DISC, not including the DISC?
1	□Unknown	
35. Patient outcome: 1	☐Survived ☐Died 3 ☐Hospitalized > 1 year 9 ☐U	Inknown
Date of discharge:	Date of deat	n:
	Unknown	Unknown
☐ Left against medical ad	vice (AMA)	
35a. Discharged to:	_	
0 □Not applicable (i.e. patie	ent died, or not hospitalized) 5 □Other	
1 □Private residence	6 ☐Homeless	
2 □LTCF Facility ID:	7 Correctional or detention fac	cility
3 LTACH Facility ID:	Q □ Drug/alcohol robabilitation	
ETACH Tucincy ID.	9 🗌 Unknown	
_	any of the following classes or specific ICD-10 codes, including the Unknown    Not applicable (i.e., patient not hospit	
B37 (candidiasis)	☐ B48 (other mycoses, not classified els	_
Specify sub-code:	_ ` , , , .	☐ R65.2 (severe sepsis)
	` ' ' ' '	
Specify sub-code:	T80.211 (BSI due to central venous of	Specify code:
☐ P37.5 (neonatal candidias	sis)	Specify code:
37. Previous Hospitalizati	on in the <u>90 days before</u> , not including the DISC: 1 Yes	0 □No 9 □Unknown
37a. If yes, date of discharge	e: Unknown	
Facility ID:		
,	$\overline{}$ ACH in the <u>90 days before</u> , not including the DISC: $1 \Box$ Ye	s 0 □No 9 □Unknown
Facility ID:		
<b>39. Overnight stay in LTO</b> Facility ID:	<b>CF in the <u>90 days before</u></b> , <b>not including the DISC:</b> 1 ☐Yes	0 □No 9 □Unknown
UNDERLYING CONDITION	ONS	
40. Underlying condition		
☐Chronic Lung Disease	☐Liver Disease	☐Plegias/Paralysis
☐Cystic Fibrosis	☐Chronic Liver Disease	☐Hemiplegia
☐Chronic Pulmonary disea	se Ascites	Paraplegia
Chronic Metabolic Dise	<u> </u>	Quadriplegia
□ Diabetes Mellitus	☐ Hepatic Encephalopathy	☐ Renal Disease
☐With Chronic Complicat		Chronic Kidney Disease
Cardiovascular Disease	· · · · ·	Lowest serum creatinine:mg/DL
□CVA/Stroke/TIA	☐Hepatitis C	☐Unknown or not done
Version: Short Form 20	D24 Last Updated: 07/29/2023	Page <b>4</b> of <b>10</b>

State ID: Date of Incider	nt Specimen Collection ( <i>mm-dd-yyyy</i> ):	Surveillance Officer Initials
Congenital Heart disease  Congestive Heart Failure  Myocardial infarction  Peripheral Vascular Disease (PVD)  Gastrointestinal Disease  Diverticular disease  Inflammatory Bowel Disease  Peptic Ulcer Disease  Short gut syndrome  Immunocompromised Condition  HIV infection  AIDS/CD4 count <200  Primary Immunodeficiency  Transplant, Hematopoietic Stem Cell  Transplant, Solid Organ (specify):	☐Treated, in SVR ☐Current, chronic ☐Hepatitis B, acute ☐Malignancy ☐Malignancy, Hematologic ☐Malignancy, Solid Organ (non-metastatic) ☐Malignancy, Solid Organ (metastatic) ☐Neurologic Condition ☐Cerebral palsy ☐Chronic Cognitive Deficit ☐Dementia ☐Epilepsy/seizure/seizure disorder ☐Multiple sclerosis ☐Neuropathy ☐Paresis ☐Parkinson's disease	□Skin Condition □Blistering disease □Burn □Decubitus/Pressure Ulcer □Eczema □Psoriasis □Surgical Wound □Other chronic ulcer or chronic wound □Other □Connective tissue disease □Obesity or morbid obesity □Pregnant
	□ Parkinson's disease □ Spinal cord injury	

Last Updated: 07/29/2023

Page **5** of **10** 

Version: Short Form 2024

State ID:	Date of Incident Specimen Collectio	n ( <i>mm-dd-yyyy</i> ):	Surveillance Officer Initials
SOCIAL HISTORY			
41. Smoking (Check all that a	apply):	42. Alcohol Abuse:	
□None documented	□Tobacco	1 □Yes	
Unknown	☐E-nicotine delivery system	0 ☐None documented	
OTIKITOWIT		9 □Unknown	
43. Other Substances (Chec	k all that apply):   None docume	 nted □Unknown	
45. Other Substances (Chee	,	Disorder (DUD/Abuse):	Mode of Delivery (Check all that apply):
☐Marijuana (other than smoki	ing)	DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, DEA schedule I (e.g.	, Heroin)	□DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, DEA schedule II-IV (	(e.g., methadone, oxycodone)	□DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, NOS		□DUD or abuse	□IDU □Non-IDU □Unknown
☐Cocaine		□DUD or abuse	□IDU □Non-IDU □Unknown
☐ Methamphetamine		DUD or abuse	□IDU □Non-IDU □Unknown
Other (specify):	_ <del></del>	DUD or abuse	□IDU □Non-IDU □Unknown
☐Unknown substance		□DUD or abuse	□IDU □Non-IDU □Unknown
			tment (MAT) for opioid use disorder?
1 □Yes 0 □No	8 N/A (patient not hospitalized or did	not have DUD) 9 □Ur	nknown
OTHER CONDITIONS			
<b>45.</b> For cases ≤ <b>1</b> year of ag	ge: Gestational age at birth:	wks 9 □Unknown ANI	D Birth weight: gms 9  Unknown
46. Chronic Dialysis:	Not on chronic dialysis   Unknown	46a. If Hemodialysis, typ	e of vascular access:
Type: ☐ Hemodialysis ☐	Peritoneal	☐ AV fistula/graft ☐	Hemodialysis central line Unknown
47. Surgeries in the 90 days	s before, not including the DISC:	48. Pancreatitis in the	90 days before, not including the DISC:
☐Abdominal surgery (specify)	:	1 □Yes	
If yes: 1 ☐Open abdomer	n 0 □Laparoscopic 9 □Unknown	0	
□Non-abdominal surgery (spe	ecify):	9 □Unknown	
□No surgery			
49. Did the patient have an	y ostomies of the gastrointestinal tr	ract including ileostomy,	colostomy, etc. in the 30 calendar days before, not
including the DISC?			
1 □Yes 0 □No 9 □	]Unknown		
50. Chronic Urinary Tract P		50a. If yes, did the patient before, not including the	nt have any urinary tract procedures in the 90 days DISC?
1 □Yes 0 □No	9 □Unknown	1	9 □Unknown
51. Was the patient neutro	penic in the 2 calendar days before,	not including the DISC?	
1	]Unknown (no WBC days -2 or 0, or no c	_	
52. Did the patient have a 0	CVC in the 2 calendar days before, n	ot including the DISC?	
1 □Yes 2 □No 3 □	]Had CVC but can't find dates 9 □Unk	known	
If yes, was the central line	in place for > 2 calendar days: 1 $\square$ Yes	0 □No 9 □Unkı	nown
52a. If yes, CVC type: (Check a	all that apply)		
□Non-tunneled CVCs	☐Implantable ports		Other (specify):
☐Tunneled CVCs	☐Peripherally inserte	ed central catheter (PICC)	□Unknown
52b. Were all CVCs removed or	r changed in the 2 days before or in the	6 days after the DISC?	
1 □Yes	3 ☐CVC removed, but can't find d		9  ☐Unknown
2  No	5 Died or discharged before ind		
	<b>nidline catheter in the 2 calendar da</b> ]Unknown	ays before, not including	the DISC?
	-		

Last Updated: 07/29/2023

Page **6** of **10** 

Version: Short Form 2024

State ID:	Date of Incident Specimen Collect	ction ( <i>mm-dd-yyyy</i> ): Surveillance Officer Initials
54. Did the patient have DISC? None Unl		ices or other devices present in the 2 calendar days before, not including the
☐Urinary Catheter/Device	Respiratory	□Gastrointestinal
☐Indwelling urethral	□ET/NT	Abdominal drain (specify):
Suprapubic	☐Tracheost	·
EE Did the nationt have		mechanical ventilation  molecular assay, antigen, or other confirmatory test, excluding serology) from
a specimen collected in	the 90 days before the DISC or on th	
1 □Yes 0 □No	9 □Unknown	
55a. If yes, date of specime	en collection for initial positive SARS-CoV-	-2 test:
Date: 9 🗆 D	Date Unknown	
55b. If yes, EIP COVID-NE	ET Case ID: None o	or N/A
•	•	n in the 14 days before, not including the DISC?
1 □Yes 0 □No 9 □U	Jnknown	
57. Did the patient rece	ive any systemic steroids in the 30 da	ays before, not including the DISC?
1 □Yes 0 □No 9 □U	Jnknown	
57a. If yes, what was the r	reason steroids were administered? (check	k all that apply)
	as an outpatient medication	sking possisked wikk goodidenin opinede
	prior to <i>Candida</i> DISC, during hospitalizates part of treatment/management for COV	·
☐ None of the above	· · · · · · · · · · · · · · · · · · ·	
58. Did the patient rece	ive total parenteral nutrition (TPN) ir	in the 14 days before, not including the DISC?
1 □Yes 0 □No 9 □U	Jnknown	
59. Did the patient rece	ive systemic antifungal medication o	on the day of or in the 13 days before the DISC?
1 □Yes (if Yes, fill out que	estion 67) 0 □No 9 □Unknown	n
60. Was the patient adn	ninistered systemic antifungal medica	cation after, not including the DISC?
1 □Yes (if Yes, fill out que	estion 67) 0 □No 9 □Unknown	n
61. If antifungal medica	 Ition was not given to treat current c	candidemia infection, what was the reason?
1 □Patient died before cul	lture result available to clinicians	5 Other reason documented in medical records, specify:
2 Comfort care only mea	asures were instituted	6 □Patient refused treatment against medical advice
	ore culture result available to clinician	9 □Unknown
4 Medical records indicat	ted culture result not clinically significant o	or
contaminated		
	IF ANY ANTIFUNGAL MEDIC	CATION WAS GIVEN, COMPLETE NEXT PAGE
OTHER		
infection?	ate that the incident specimen was c	considered a contaminant or was considered to not be indicative of true
1 □Yes 0 □No	9 □Unknown	
63. Was the patient und	er the care of an infectious disease p	physician on the day of the DISC or within the 6 days after the DISC?
1 □Yes 0 □No	9 □Unknown	
64. Did the patient have after the DISC?	an echocardiogram (ECHO), includir	ng transthoracic (TTE) or transesophogeal (TEE), on the day of or 13 days
1 □Yes 0 □No	9 □Unknown	
65. Did the patient have	a dilated fundoscopic eye exam on t	the day of or 13 days after the DISC?
1 □Yes 0 □No	9 □Unknown	
66. Is case associated w	vith a known outbreak?	
1	9  ☐Unknown	

Version: Short Form 2024 Last Updated: 07/29/2023 Page **7** of **10** 

lulafungin (	Some, etc.)=AMBIV (Eraxis)=ANF Cancidas)=CAS	Fli Is Itı	uconazole (Diflucan)=FLC ucytosine (5FC)=5FC avuconazole (Cresemba)=ISU raconazole (Sporanox)=ITC icafungin (Mycamine)=MFG	Po Re UI	cher=OTH saconazole (Noxafil)=PSC ezafungin (Rezzayo)= RZF NKNOWN DRUG=UNK oriconazole (Vfend)=VRC	
ANTIFUN a. Drug Abbrev	GAL MEDICATION  b. First date given (mm-dd-	c. Date start unknown	d. Last date given (mm-dd-yyyy)	e. Date stop unknown	f. Indication g	. Reason for stopping (if applicable)*
					Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
		🗆			Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	

Version: Short Form 2024Last Updated: 07/29/2023Page 8 of 10

AFST results for additional Candida isolates	tate ID:	Date of I	ncident Specimen Collection	n ( <i>mm-dd-yy</i>	yy): Surveillance Officer Initials		
			AFCT seeks for a	.d.d!s! 1	0 4'-4- ! Ik		
Date of culture							
1   CA	Date of culture	•		МІС	·		
Caspofungin (Cancidas)							
		2 □CG					
S							
6			, ,				
			, , ,				
9   CO   Posaconazole (Novafi)   S   SDD   I   R   NI   ND     10   CGN   Rezafungin (Rezzayo)   S   SDD   I   R   NI   ND     12   Pending   Voriconazole (Vfend)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     2   CG   Caspofungin (Cancidas)   S   SDD   I   R   NI   ND     4   CT   Fluconazole (Vifuan)   S   SDD   I   R   NI   ND     5   CD   Flucytosine (SFC)   S   SDD   I   R   NI   ND     6   CL   Itraconazole (Sporanox)   S   SDD   I   R   NI   ND     9   CC   Posaconazole (Novafil)   S   SDD   I   R   NI   ND     11   CS   Rezafungin (Rezzayo)   S   SDD   I   R   NI   ND     11   CS   Rezafungin (Rezzayo)   S   SDD   I   R   NI   ND     11   CA   Anidulafungin (Fraxis)   S   SDD   I   R   NI   ND     11   CA   Rezafungin (Rezzayo)   S   SDD   I   R   NI   ND     12   Pending   Voriconazole (Novafil)   S   SDD   I   R   NI   ND     11   CA   Anidulafungin (Fraxis)   S   SDD   I   R   NI   ND     12   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     13   CAU   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     14   CT   Fluconazole (Sporanox)   S   SDD   I   R   NI   ND     15   CA   Amphotericin B   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CG   Posaconazole (Novafil)   S   SDD   I   R   NI   ND     1   CG   Posaconazole (Novafil)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND     1   CA   Anidulafungin (Eraxis)   S   SDD   I   R   NI   ND							
10   GN   11   GS   Rezafungin (Rezzayo)							
1			, ,				
1			Voriconazole (Vfend)				
1			Amphotericin B				
Caspofungin (Cancidas)			Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND		
4   CT   Fluconazole (Diflucan)   S   SDD   I   R   NI   ND		2 □CG	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND		
Flucytosine (SFC)			Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND		
Traconazole (Sporanox)		5 □CD	Flucytosine (5FC)		□S □SDD □I □R □NI □ND		
8   CGM			Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND		
10			Micafungin (Mycamine)		□S □SDD □I □R □NI □ND		
11			Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND		
Voriconazole (Vrend)			Rezafungin (Rezzayo)		□S □SDD □I □R □NI □ND		
Date of culture   Species   Drug   MIC   Interpretation     1		12 ☐Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND		
CA	ntifungal suscepti	bility testing (ch	eck here $\square$ if no testing do	ne/no test re	ports available):		
CA	Date of culture	Species	Drug	MIC	Interpretation		
2		1	Amphotericin B		□S □SDD □I □R □NI □ND		
3   CP			Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND		
A			Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND		
6		4 □CT	Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND		
7			Flucytosine (5FC)		□S □SDD □I □R □NI □ND		
9			Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND		
10			Micafungin (Mycamine)		□S □SDD □I □R □NI □ND		
11			Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND		
1		11 □CS	Rezafungin (Rezzayo)		□S □SDD □I □R □NI □ND		
1		12 ☐Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND		
13		1 □CA	Amphotericin B		□S □SDD □I □R □NI □ND		
3		13 □CAU	Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND		
4			Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND		
			Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND		
			Flucytosine (5FC)		□S □SDD □I □R □NI □ND		
6 CL Itraconazole (Sporanox) S SDD I R NI ND		lo □CL	Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND		

Version: Short Form 2024 Last Updated: 07/29/2023 Page **9** of **10** 

State ID: Date of	Incident Specimen Collection (mm-dd	· <i>үүүү</i> ):	Surveillance	e Officer Initials
7 □CK	Micafungin (Mycamine)	□S	□SDD □I □R	□NI □ND
8 □CGM	Posaconazole (Noxafil)	□S	□SDD □I □R	
9 □CO 10 □CGN	Rezafungin (Rezzayo)	□S		
11 □CS 12 □Pending	Voriconazole (Vfend)		□SDD □I □R	
12 Eli chang				

Last Updated: 07/29/2023

Page **10** of **10** 

Version: Short Form 2024